SecBot SecBot
8-K ·Filed Mar 31, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
MIXED
Impact 6/10
Horizonweeks Processed7mo ago SEC0001193125-26-133332
earnings-rerun-backfill
Actionable Insight ◆ Mixed

Monitor the upcoming NDA submission for QTORIN rapamycin in microcystic LMs and the initiation of new clinical trials in 2026, as these will be key catalysts for the stock. The earnings miss may pressure the share price short-term, but the strong cash position reduces near-term dilution risk.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$124.65
T+0 close · Mar 31, 2026 · via day close
Latest settled
+18.90%
T+60 · $148.21
Vs SPY
+6.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 31 $124.65entry
  2. T+1 · 8mo ago −3.43%α −4.17% · $120.38
  3. T+5 · 7mo ago −1.19%α −5.13% · $123.17
  4. T+20 · 7mo ago −2.81%α −12.23% · $121.15
  5. T+60 · 5mo ago +18.90%α +6.52% · $148.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics reported Q4 2025 financial results with a net loss of $41.7 million ($3.71 per share), missing consensus by 15.4%. However, the company highlighted strong clinical progress, including positive Phase 3 data for QTORIN rapamycin in microcystic lymphatic malformations and a $230 million equity financing, leaving it with $274 million in pro forma cash. The stock may react negatively to the earnings miss but could be supported by the robust pipeline advancement and strengthened balance sheet.

Key Financial Metrics

EPS
−$1.07
est −$0.93 · -15.1%
Revenue
$0.00
est $0.00 · 0.0%
Rating
miss

Key Facts

  • Net loss of $41.7 million for 2025, or $3.71 per share, missing consensus of $-0.93 by 15.4%.
  • Raised $230 million in an oversubscribed public offering, resulting in $274 million of pro forma cash as of December 31, 2025.
  • Reported positive Phase 3 SELVA study results for QTORIN rapamycin in microcystic lymphatic malformations, with NDA submission on track for 2H 2026.
  • Initiation of Phase 3 trials for QTORIN rapamycin in cutaneous venous malformations and Phase 2 trials for two other indications are planned for 2026.
  • Research and development expenses increased to $22.8 million in 2025 from $8.2 million in 2024.

Financial Impact

Net loss of $41.7 million for 2025, with a $230 million equity raise significantly bolstering the balance sheet to $274 million in pro forma cash.

epscashr&d_expenses

Risk Factors

  • Continued high R&D and G&A expenses could pressure the cash runway despite the recent financing.
  • Clinical trial setbacks or regulatory delays could negatively impact the company's valuation.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-133332
Document: pvla-20260331.htm0001193125-26-133332
Document: pvla-ex99_2.htm0001193125-26-133332
Document: 0001193125-26-133332-index-headers.html0001193125-26-133332
Document: 0001193125-26-133332-index.html0001193125-26-133332
Document: 0001193125-26-133332.txt0001193125-26-133332
8-K Data (Synthetic)0001193125-26-133332

Track record

36 reports on PVLA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
  2. Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
  3. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
  4. Nov 5, 202611d ago Press Release Neutral 6/10 No price data
  5. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
  6. Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  7. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  8. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
  9. Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
  10. Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026